NurseJet
Back to Discover
Research ArticleResearchWorkflowPatient Education

Implantable ports had fewer major complications than PICCs in one chemotherapy trial

The Pan African Medical Journal (PubMed)May 12, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a single-center randomized study of adults receiving chemotherapy for non-hematologic cancers, major complications occurred more often with PICCs than implantable ports during six months of follow-up.

What NurseJet pulled from the source

Of 206 randomized patients, 192 were analyzed. Major complications occurred in 17.8% of the PICC group and 4.9% of the port group; ports cost more for treatment lasting under six months, and overall quality of life did not differ significantly.

Why this matters for nurses

Oncology nurses assess treatment duration, device function, skin and access sites, patient preferences, and the ability to manage a device at home. The trial highlights a complication-cost tradeoff that belongs in individualized vascular-access planning.

Bedside takeaway

Vascular-access choice should balance complication risk, treatment duration, cost, maintenance needs, and patient preference.

How This Applies in Practice

Use this when: Supporting vascular-access planning or ongoing device care for an adult receiving chemotherapy for a non-hematologic cancer.

On your shift

  • Confirm treatment duration, prescribed device, access restrictions, maintenance schedule, and responsible follow-up team.
  • Assess the site and device function before use and complete approved access, dressing, flushing, and infection-prevention steps.
  • Use teach-back for home care and symptoms that require stopping use and contacting the oncology team promptly.
Keep in mind: One single-center trial does not establish the best device for every patient, and local costs differ. Follow the oncology vascular-access protocol, facility policy, and provider orders.

Key takeaways

  • The prospective randomized study assigned 206 adults to a PICC or implantable port and analyzed 192.
  • Major complications occurred in 17.8% with PICCs and 4.9% with ports.
  • Ports cost more than PICCs when chemotherapy lasted less than six months.
  • Overall quality of life did not differ significantly between groups.

Practice implications

  • Verify the selected device and maintenance plan, assess the site and line function before use, and follow the approved dressing, flushing, access, and infection-prevention procedures. Teach patients to report pain, swelling, redness, drainage, fever, resistance, leakage, or device damage promptly.

Limitations & cautions

  • The study was conducted at one center, 14 randomized participants were not included in the analysis, and the abstract does not detail individual complication types or blinding. Costs reflect one health system and may not generalize elsewhere.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Pan African Medical Journal (PubMed)

The Pan African Medical Journal (PubMed). [The role of central vascular access in the management of patients receiving chemotherapy for non-hematological malignant tumors: PICC line versus implantable Ports].

Open original source

https://pubmed.ncbi.nlm.nih.gov/42542825/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Journal of clinical oncology (PubMed)

In the MATCH comparative effectiveness trial of 587 cancer survivors, both mindfulness-based cancer recovery and Tai Chi/Qigong significantly reduced post-treatment fatigue and pain interference compared to controls, with Tai Chi also significantly improving sleep quality.

OncologyMed-SurgAI summaryReview source

Intensive care medicine (PubMed)

The 18-center TRANSPORT randomized trial of 187 cancer patients with septic shock found that a liberal transfusion strategy (Hb threshold 9.0 g/dL) did not improve 12-hour lactate clearance (52% vs 50%) or 28-day survival over a restrictive strategy (Hb threshold 7.0 g/dL), but increased thrombotic events from 1% to 13%.

ICUOncologyAI summaryReview source

Palliative & Supportive Care (PubMed)

A systematic review of 14 studies found that nurse-led predictive symptom management combining routine laboratory biomarkers with clinical nursing assessment enabled proactive intervention, decreased emergency department visits, and enhanced symptom control in cancer palliative care.

OncologyGeriatricsAI summaryReview source